Review of the Ticagrelor Trials Evidence Base

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Ticagrelor is a P2Y12 receptor inhibitor indicated for acute coronary syndromes, coronary artery disease, and specific ischemic stroke/transient ischemic attack cases.
• Numerous clinical trials have assessed ticagrelor's efficacy and safety, yielding substantial data on ischemic and bleeding outcomes.
• The net clinical benefit of ticagrelor varies significantly based on patient characteristics, clinical presentation, and treatment strategies when compared to other antiplatelet agents.

Purpose of the Study:

• To review major ticagrelor trials within the context of clopidogrel and prasugrel randomized trials.
• To organize the extensive clinical evidence on ticagrelor, clopidogrel, and prasugrel.
• To identify corroborating and conflicting data, and pinpoint gaps for future research on optimal antiplatelet treatment.

Main Methods:

• Systematic review and comparative analysis of major randomized controlled trials.
• Inclusion of trials evaluating ticagrelor, clopidogrel, and prasugrel in relevant patient populations.
• Focus on ischemic and bleeding outcomes to assess net clinical benefit.

Main Results:

• Ticagrelor demonstrates varied net clinical benefit across different indications and patient subgroups.
• Comparative analysis highlights differences in efficacy and safety profiles among ticagrelor, clopidogrel, and prasugrel.
• Evidence synthesis reveals areas of consensus and discordance regarding optimal antiplatelet therapy.

Conclusions:

• Optimal antiplatelet treatment with ticagrelor, clopidogrel, or prasugrel is highly individualized.
• Further research is needed to address identified gaps in understanding treatment duration and patient selection for maximal net clinical benefit.
• This review provides a framework for navigating complex antiplatelet treatment decisions in cardiovascular and cerebrovascular diseases.